Tonix Pharmaceuticals Holding Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT ACCOUNTING POLICIES (Tables)

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of maturities for marketable securities

Marketable securities owned at December 31, 2017 and 2016, all of which have maturities of 1 year or less as of such date, were as follows (in thousands):

1 Year or Less


	December 31, 2017		December 31, 2016
U.S. Treasury bond	$	-	$	2,752
U.S agency bonds		-		1,254
Certificates of deposit		-		3,174
Total	$	-	$	7,180

Schedule of accumulated other comprehensive income

The following table summarizes the changes in accumulated other comprehensive income by component (in thousands):

	Foreign Currency Translation Adjustment			Unrealized Gains (Losses) on available for sale securities		Total
Balance at December 31, 2015		10			(27)		(17)
Other Comprehensive (Loss) Gain		(17)			27		10
Balance at December 31, 2016		(7)			-		(7)
Other Comprehensive Loss		(5)			-		(5)
Balance at December 31, 2017		(12	)		-		(12	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details